Endo Announces Divestiture of International Pharmaceuticals Business
Endo (OTCQX: NDOI) has announced the divestiture of its International Pharmaceuticals business, primarily operated through Paladin Pharma Inc., to Knight Therapeutics Inc. for up to $99 million. The deal structure includes an $84 million upfront cash payment and potential additional $15 million in milestone-based payments.
Knight Therapeutics, specializing in innovative prescription pharmaceuticals in Canada and Latin America, will acquire Paladin Pharma, Endo's Canada-based specialty pharmaceutical subsidiary. The transaction, subject to regulatory approvals including Canadian anti-trust clearance, is expected to close in mid-2025.
Endo (OTCQX: NDOI) ha annunciato la cessione della sua attività di farmaci internazionali, principalmente operata attraverso Paladin Pharma Inc., a Knight Therapeutics Inc. per un massimo di 99 milioni di dollari. La struttura dell'accordo prevede un pagamento iniziale in contante di 84 milioni di dollari e potenziali ulteriori 15 milioni di dollari in pagamenti legati a traguardi.
Knight Therapeutics, specializzata in farmaci innovativi da prescrizione in Canada e America Latina, acquisirà Paladin Pharma, la filiale farmaceutica specializzata di Endo con sede in Canada. La transazione, soggetta ad approvazioni regolatorie, inclusa l'autorizzazione antitrust canadese, è prevista per la conclusione a metà del 2025.
Endo (OTCQX: NDOI) ha anunciado la desinversión de su negocio de productos farmacéuticos internacionales, principalmente operado a través de Paladin Pharma Inc., a Knight Therapeutics Inc. por hasta 99 millones de dólares. La estructura del acuerdo incluye un pago inicial en efectivo de 84 millones de dólares y posibles 15 millones de dólares adicionales en pagos basados en hitos.
Knight Therapeutics, especializada en productos farmacéuticos innovadores con receta en Canadá y América Latina, adquirirá Paladin Pharma, la subsidiaria farmacéutica especializada de Endo con sede en Canadá. La transacción, sujeta a aprobaciones regulatorias, incluida la autorización antimonopolio canadiense, se espera que se cierre a mediados de 2025.
Endo (OTCQX: NDOI)는 Paladin Pharma Inc.를 통해 주로 운영되는 국제 제약 사업을 Knight Therapeutics Inc.에 최대 9,900만 달러에 매각한다고 발표했습니다. 거래 구조에는 8,400만 달러의 선불 현금 지급과 추가로 1,500만 달러의 이정표 기반 지급이 포함됩니다.
혁신적인 처방약을 전문으로 하는 Knight Therapeutics는 캐나다와 라틴 아메리카에서 Paladin Pharma를 인수할 예정입니다. 이 거래는 캐나다의 반독점 승인 등 규제 승인을 받아야 하며, 2025년 중반에 마무리될 것으로 예상됩니다.
Endo (OTCQX: NDOI) a annoncé la cession de son activité pharmaceutique internationale, principalement opérée par Paladin Pharma Inc., à Knight Therapeutics Inc. pour un montant pouvant atteindre 99 millions de dollars. La structure de l'accord comprend un paiement initial en espèces de 84 millions de dollars et des paiements supplémentaires potentiels de 15 millions de dollars basés sur des jalons.
Knight Therapeutics, spécialisée dans les médicaments innovants sur ordonnance au Canada et en Amérique latine, va acquérir Paladin Pharma, la filiale pharmaceutique spécialisée d'Endo basée au Canada. La transaction, soumise à des approbations réglementaires, y compris l'autorisation antitrust canadienne, devrait se clôturer à mi-2025.
Endo (OTCQX: NDOI) hat die Veräußerung seines internationalen Pharma-Geschäfts, das hauptsächlich über Paladin Pharma Inc. betrieben wird, an Knight Therapeutics Inc. für bis zu 99 Millionen Dollar angekündigt. Die Struktur des Deals umfasst eine sofortige Barzahlung von 84 Millionen Dollar und potenzielle zusätzliche 15 Millionen Dollar in leistungsabhängigen Zahlungen.
Knight Therapeutics, spezialisiert auf innovative verschreibungspflichtige Arzneimittel in Kanada und Lateinamerika, wird Paladin Pharma, die in Kanada ansässige Spezialpharmazeutiktochter von Endo, erwerben. Die Transaktion, die noch der behördlichen Genehmigung, einschließlich der kanadischen Wettbewerbsaufsicht, bedarf, wird voraussichtlich mitte 2025 abgeschlossen sein.
- Immediate cash injection of $84 million
- Potential additional $15 million from milestone payments
- Strategic alignment with core-growth assets focus
- Reduction in international market presence
- Loss of revenue stream from Canadian operations
Knight Therapeutics is a specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, marketing and commercializing innovative prescription pharmaceuticals, primarily serving
"This divestiture is an important step forward in our strategic transformation and focus on investing in our core-growth assets," said Scott Hirsch, Interim CEO of Endo. "We are confident that Paladin is well positioned for continued success in the Canadian market and that Knight Therapeutics is the right partner for Paladin's next chapter. We are grateful to the talented Paladin team for their dedication and many contributions."
The closing of the transaction is subject to the satisfaction of customary regulatory conditions including anti-trust clearance in Canada and is expected to occur in mid-2025.
About Endo
Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited, to any statements by Mr. Hirsch, any statements relating to the divestiture of the International Pharmaceuticals business and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: the parties' ability to satisfy the conditions to the divestiture of the International Pharmaceuticals business, including required regulatory approvals; the ability to complete the divestiture on the anticipated timeline or at all; the potential impact of the divestiture on Endo's businesses; the risk that consummating the divestiture may be more difficult, time-consuming and costly than expected; changes in competitive, market or regulatory conditions; changes in legislation or regulations; the ability to obtain and maintain adequate protection for intellectual property rights; the impacts of competition; the timing and uncertainty of the results of the research and development and the regulatory processes; health care and cost containment reforms, including government pricing, tax and reimbursement policies; litigation and other disputes; consumer and physician acceptance of current and new products; the performance of third parties upon whom we rely for goods and services; issues associated with our supply chain; the ability to develop and expand our product pipeline, to launch new products and to continue to develop the market for our products; and the effectiveness of advertising and other promotional campaigns. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/endo-announces-divestiture-of-international-pharmaceuticals-business-302397770.html
SOURCE Endo, Inc.
FAQ
How much is Knight Therapeutics paying for Endo's (NDOI) International Pharmaceuticals business?
When is the Endo (NDOI) and Knight Therapeutics deal expected to close?
What assets are included in Endo's (NDOI) divestiture to Knight Therapeutics?
What regulatory approvals are needed for the Endo (NDOI) divestiture?
